ACT 132577

Drug Profile

ACT 132577

Alternative Names: AC 080; ACT-132577

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension
  • Phase I Cardiovascular disorders

Most Recent Events

  • 18 Apr 2017 Actelion completes a phase I trial in Hypertension (In volunteers) in the Netherlands (NCT03100591)
  • 31 Mar 2017 Actelion completes a phase-II trial in Hypertension in Puerto Rico, Israel, Canada, USA (NCT02603809)
  • 08 Mar 2017 Phase-I clinical trials in Hypertension (In volunteers) in Netherlands (PO) (NCT03100591)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top